NanoViricides Inc. (NNVC)

[drkazmd65]

You can read it as well as I can. The PR doesn't actually show 'the actual data' - but does go through the dosing schemes for both oral gummies and liquid forms that were the tested concentrations of NV-387.

The PR also makes a similar statement in the section talking about the lack of toxicity in all of the pre-clinical (animal and other model systems) that they tested the compounds in

NV-387 has been found to be non-immunogenic, non-allergenic, non-mutagenic, as well as non-genotoxic in various pre-clinical animal model studies leading to the clinical trials. No adverse effects were reported in GLP Safety-Toxicology studies in multiple animal models including non-human primates (NHP, Cynomolgus monkeys). The NOAEL (No-Observed-Adverse-Events-Level) was 1,200 mg/Kg and MTD (Maximum Tolerable Dose) was 1,500 mg/Kg in rats, which indicate excellent safety.

that is right before the statement about other antiviral drugs having dose-limiting toxicities. So I assume that's where they are drawing that conclusion - not from specifically this Phase Ia/b trial.

I assume that the 'final report' will have more details once the biostats guys have had a chance to do their thing.